eprintid: 10175867 rev_number: 6 eprint_status: archive userid: 699 dir: disk0/10/17/58/67 datestamp: 2023-08-30 15:12:31 lastmod: 2023-08-30 15:12:31 status_changed: 2023-08-30 15:12:31 type: article metadata_visibility: show sword_depositor: 699 creators_name: Gonçalves, Lisa creators_name: Gonçalves, Duarte creators_name: Esteban-Casanelles, Teresa creators_name: Barroso, Tiago creators_name: Soares de Pinho, Inês creators_name: Lopes-Brás, Raquel creators_name: Esperança-Martins, Miguel creators_name: Patel, Vanessa creators_name: Torres, Sofia creators_name: Teixeira de Sousa, Rita creators_name: Mansinho, André creators_name: Costa, Luís title: Immunotherapy around the Clock: Impact of Infusion Timing on Stage IV Melanoma Outcomes ispublished: pub divisions: UCL divisions: B03 divisions: C03 divisions: F24 keywords: Cancer, chronobiology, circadian, immunotherapy, melanoma note: This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third-party material in this article are included in the Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ abstract: Although the impact of circadian timing on immunotherapy has yet to be integrated into clinical practice, chronoimmunotherapy is an emerging and promising field as circadian oscillations are observed in immune cell numbers as well as the expression of immunotherapy targets, e.g., programmed cell death protein-1 and its ligand programmed death ligand 1. Concurrent retrospective studies suggest that morning infusions may lead to higher effectiveness of immune checkpoint inhibitors in melanoma, non-small cell lung cancer, and kidney cancer. This paper discusses the results of a retrospective study (2016-2022) exploring the impact of infusion timing on the outcomes of all 73 patients with stage IV melanoma receiving immunotherapy at a particular medical center. While the median overall survival (OS) was 24.2 months (95% confidence interval [CI] 9.04-39.8), for a median follow-up of 15.3 months, our results show that having more than 75% of infusions in the afternoon results in shorter median OS (14.9 vs. 38.1 months; hazard ratio 0.45 [CI 0.23-0.86]; p < 0.01) with more expressive impacts on particular subgroups: women, older patients, and patients with a lower tumor burden at the outset of immunotherapy. Our findings highlight the potential benefits of follow-up validation in prospective and translational randomized studies. date: 2023-08-15 date_type: published publisher: MDPI AG official_url: https://doi.org/10.3390/cells12162068 oa_status: green full_text_type: pub language: eng primo: open primo_central: open_green verified: verified_manual elements_id: 2080940 doi: 10.3390/cells12162068 medium: Electronic pii: cells12162068 lyricists_name: Goncalves Dias Da Silva, Duarte lyricists_id: DGONC71 actors_name: Flynn, Bernadette actors_id: BFFLY94 actors_role: owner full_text_status: public publication: Cells volume: 12 number: 16 article_number: 2068 event_location: Switzerland citation: Gonçalves, Lisa; Gonçalves, Duarte; Esteban-Casanelles, Teresa; Barroso, Tiago; Soares de Pinho, Inês; Lopes-Brás, Raquel; Esperança-Martins, Miguel; ... Costa, Luís; + view all <#> Gonçalves, Lisa; Gonçalves, Duarte; Esteban-Casanelles, Teresa; Barroso, Tiago; Soares de Pinho, Inês; Lopes-Brás, Raquel; Esperança-Martins, Miguel; Patel, Vanessa; Torres, Sofia; Teixeira de Sousa, Rita; Mansinho, André; Costa, Luís; - view fewer <#> (2023) Immunotherapy around the Clock: Impact of Infusion Timing on Stage IV Melanoma Outcomes. Cells , 12 (16) , Article 2068. 10.3390/cells12162068 <https://doi.org/10.3390/cells12162068>. Green open access document_url: https://discovery.ucl.ac.uk/id/eprint/10175867/1/cells-12-02068.pdf